Zolpidem and Zopiclone for Insomnia Treatment
Comparative Efficacy
- Zolpidem reduces sleep onset latency by approximately 15-19 minutes compared to placebo and increases total sleep time by 23 minutes in pooled trials, according to the American College of Physicians 1, 2
- The American College of Physicians recommends zolpidem, which improves the proportion of patients "getting a better night's sleep" (69% vs 49% placebo) 1
Safety and Tolerability Profile
- Zolpidem's most common adverse effects include nausea, dizziness, and drowsiness, with withdrawals due to adverse effects occurring in 6% vs 3% with placebo, as reported by the American College of Physicians 1, 2
- Zolpidem carries FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking), psychiatric adverse events, memory impairment, and driving impairment, according to the American College of Physicians 1, 2
- Zolpidem is associated with increased fracture risk (adjusted OR 1.72) and major head injury requiring hospitalization (adjusted HR 1.67), as reported by the American College of Physicians 1, 2
Important Clinical Caveats
- The American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before pharmacologic options, and both agents are FDA-approved for short-term use only (≤4 weeks) 1
- Insomnia persisting beyond 7-10 days requires evaluation for underlying sleep disorders such as sleep apnea, according to the American Academy of Sleep Medicine, although this specific fact is from Praxis Medical Insights, an alternative source is not provided 3
- Counsel all patients about risks of complex sleep behaviors, driving impairment, and fall risk, particularly in the first few hours after administration, as advised by the American College of Physicians 1, 2
- Elderly patients require dose reduction with both agents (zolpidem 5mg) due to altered pharmacokinetics and increased fall risk, as recommended by the American Geriatrics Society 1